---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-044593"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2024-04-16T23:59:59+00:00"
generated_at: "2026-06-03T22:21:50.685115+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cullinan raises $280M, pivots to autoimmune with promising CLN-978 data; cash runway into 2028

## Summary
- $280M private placement at $19/share; pre-funded warrants $18.999; extends cash runway into 2028.
- Strategic pivot to autoimmune diseases; first indication systemic lupus erythematosus (SLE); IND planned Q3 2024.
- CLN-978 Phase 1 B-NHL data: 1 complete response, rapid B cell depletion, low-grade CRS, no ICANS.
- Name change to Cullinan Therapeutics (Nasdaq: CGEM); reflects expanded focus beyond oncology.
- Enrollment in B-NHL study discontinued to focus on autoimmune development.

## SEC filing metadata
- accession: 0000950170-24-044593
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2024-04-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 5.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000095017024044593/0000950170-24-044593-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000095017024044593/cgem-20240415.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-044593
- JSON: https://secwatch.observer/filing/0000950170-24-044593.json
- Plain text: https://secwatch.observer/filing/0000950170-24-044593.txt

## Key facts
- Governance Changes
  Cullinan Therapeutics, Inc.: Amended certificate of incorporation to change company name from Cullinan Oncology, Inc. to Cullinan Therapeutics, Inc (effective 2024-04-15).
  - Change: charter amendment
  - Effective: 2024-04-15
  source text: Effective as of 9:47 A.M., Eastern Time on April 15, 2024, the Company amended its Second Amended and Restated Certificate of Incorporation, as amended (the “ Certificate of Incorporation ”), to effect a change of the Company’s name from “Cullinan Oncology, Inc.” to “Cullinan Therapeutics, Inc.” (the “ Name Change ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000095017024044593/0000950170-24-044593-index.htm
- Governance Changes
  Cullinan Therapeutics, Inc.: Amended and restated bylaws solely to reflect the name change (effective 2024-04-15).
  - Change: bylaw amendment
  - Effective: 2024-04-15
  source text: the Board also approved an amendment and restatement of the Company’s Second Amended and Restated Bylaws solely to reflect the Name Change (as amended and restated, the “ Third Amended and Restated Bylaws ”) effective as of April 15, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000095017024044593/0000950170-24-044593-index.htm
- Material Agreements
  Cullinan Therapeutics, Inc. entered into Stock Purchase Agreement with certain institutional accredited investors valued at $280M gross proceeds for sale of 14,421,070 shares at $19.00/share and 315,790 pre-funded warrants a (effective 2024-04-15).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional accredited investors
  - Value: $280M gross proceeds for sale of 14,421,070 shares at $19.00/share and 315,790 pre-funded warrants a
  - Effective: 2024-04-15
  source text: On April 15, 2024, Cullinan Therapeutics, Inc. (formerly known as Cullinan Oncology, Inc.) (the “ Company ”) entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) for a private placement (the “ Private Placement ”) with certain institutional accredited investors named therein (each, a “ Purchaser ” and collectively, the “ Purchasers ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000095017024044593/0000950170-24-044593-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.